Primary Myelofibrosis Pipeline: 55+ Companies Driving Innovations in Treatment and Disease Management | DelveInsight

The treatment landscape for Primary Myelofibrosis (PMF), a rare and chronic bone marrow disorder, is advancing significantly, fueled by innovative therapies from leading pharmaceutical and biotech companies. Key players such as Nippon Shinyaku and Kartos Therapeutics are developing novel treatments aimed at targeting the underlying disease mechanisms, including JAK-STAT signaling, fibrosis, and hematopoiesis. These emerging therapies aim to improve symptoms, reduce spleen size, alleviate anemia, and ultimately improve survival rates for patients suffering from PMF.

DelveInsight's "Primary Myelofibrosis - Pipeline Insight, 2025" comprehensively analyzes the current clinical development landscape, with detailed insights into investigational therapies spanning early-stage to late-stage clinical trials. The report explores the mechanisms of action of each drug, the development phases, and the projected timelines for market entry.

This pipeline report provides a 360° view of Primary Myelofibrosis therapeutic trends, including drug types, routes of administration, and stages of clinical development. Furthermore, it highlights unmet needs, strategic collaborations, regulatory designations, and emerging market dynamics that are expected to shape the future treatment paradigm for Primary Myelofibrosis.

Interested in learning more about the current treatment landscape and the key drivers shaping the primary myelofibrosis pipeline? Click here: https://www.delveinsight.com/report-store/primary-myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Primary Myelofibrosis Pipeline Report
• DelveInsight's primary myelofibrosis pipeline analysis depicts a strong space with 55+ active players working to develop 55+ pipeline drugs for Primary Myelofibrosis treatment.
• The leading primary myelofibrosis companies include Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma Oncology, and others are evaluating their lead assets to improve the Primary Myelofibrosis treatment landscape.
• Key primary myelofibrosis pipeline therapies in various stages of development include NS 018, KRT-232, TP 3654, and others.
• In April 2025, a study published in Blood Cancer Journal reported that OJJAARA demonstrated real-world efficacy in treating myelofibrosis patients with anemia, confirming clinical trial findings.
• In March 2025, a study published in Cancer Network reported that the combination of pelabresib and ruxolitinib improved spleen responses in patients with myelofibrosis, showing promise for JAK inhibitor-naïve individuals.
• In March 2025, Memorial Sloan Kettering Cancer Center announced results from a phase III clinical trial for primary myelofibrosis, demonstrating that combining pelabresib with ruxolitinib was more effective than ruxolitinib alone in reducing spleen size and symptoms, with no significant increase in side effects
• In February 2025, Geron Corporation announced that its Phase III IMpactMF trial for imetelstat, targeting JAK inhibitor-relapsed/refractory intermediate-2 or high-risk myelofibrosis, had reached 80% enrollment. Interim analysis is expected in the second half of 2026.
• In February 2025, HealthTree for Myelofibrosis reported results from the phase III BOREAS study, presented at the 2024 ASH conference, showing navtemadlin outperformed best available therapy in patients with JAK inhibitor relapsed/refractory myelofibrosis, offering a new treatment option.

Request a sample and discover the recent breakthroughs happening in the primary myelofibrosis pipeline landscape @ https://www.delveinsight.com/report-store/primary-myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Primary Myelofibrosis Overview
Primary myelofibrosis, also known as chronic idiopathic myelofibrosis, is a disorder where the bone marrow is gradually replaced by fibrous scar tissue, leading to bone marrow failure. This happens when chemicals from abnormal platelet-forming cells overstimulate fibroblasts, resulting in thick, coarse fibres that replace healthy bone marrow tissue. This disrupts the production of red blood cells, white blood cells, and platelets, causing anaemia, low platelet counts, and enlarged spleen and liver.

Primary myelofibrosis is a rare disease, usually diagnosed in people aged 60 to 70, and can be classified as JAK2 mutation positive or negative. Though the cause is unclear, exposure to benzene or high doses of radiation may increase the risk. Symptoms develop gradually and include fatigue, weakness, shortness of breath, and enlarged spleen and liver. Some individuals may experience abdominal discomfort, indigestion, or joint pain.

Diagnosis involves physical exams, blood tests, and bone marrow examination. While incurable, treatment can help manage symptoms, and some patients may live with the disease for years with minimal disruption. The disease progression varies, with some cases remaining stable, while others require active treatment.

Find out more about primary myelofibrosis medication @ https://www.delveinsight.com/report-store/primary-myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Primary Myelofibrosis Treatment Analysis: Drug Profile
NS 018: Nippon Shinyaku
Ilginatinib (formerly known as NS 018) is a potent inhibitor targeting Janus kinase 2 (JAK2) enzyme activity and Src-family kinases. Developed by Nippon Shinyaku, it is currently undergoing Phase II clinical trials for the treatment of Primary Myelofibrosis.

KRT-232: Kartos Therapeutics
Navtemadlin (KRT-232) is a novel, potent, and selective oral MDM2 inhibitor. By targeting the MDM2-p53 interaction, it offers a promising therapeutic option for patients with Myelofibrosis (MF), Polycythemia Vera (PV), Acute Myeloid Leukemia (AML), and Merkel Cell Carcinoma (MCC). The drug is currently in Phase II/III clinical trials for Primary Myelofibrosis.

TP 3654: Sumitomo Pharma Oncology
TP-3654 is an oral investigational inhibitor of PIM kinases, showing potential antitumor and anti-fibrotic effects through multiple mechanisms, including apoptosis induction. It is currently in Phase I/II clinical trials for the treatment of Primary Myelofibrosis.

Learn more about the novel and emerging primary myelofibrosis pipeline therapies @ https://www.delveinsight.com/report-store/primary-myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Primary Myelofibrosis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Primary Myelofibrosis Pipeline Report
• Coverage: Global
• Key Primary Myelofibrosis Companies: Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma Oncology, and others.
• Key Primary Myelofibrosis Pipeline Therapies: NS 018, KRT-232, TP 3654, and others.

Dive deep into rich insights for drugs used for primary myelofibrosis treatment; visit @ https://www.delveinsight.com/report-store/primary-myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Primary Myelofibrosis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Primary Myelofibrosis Pipeline Therapeutics
6. Primary Myelofibrosis Pipeline: Late-Stage Products (Phase III)
7. Primary Myelofibrosis Pipeline: Mid-Stage Products (Phase II)
8. Primary Myelofibrosis Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.